BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/29/2025 9:14:59 AM | Browse: 105 | Download: 387
 |
Received |
|
2025-01-21 02:47 |
|
Peer-Review Started |
|
2025-01-21 02:47 |
|
First Decision by Editorial Office Director |
|
2025-03-24 10:15 |
|
Return for Revision |
|
2025-03-24 10:15 |
|
Revised |
|
2025-04-04 18:55 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-05-06 06:58 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-05-13 07:39 |
|
Articles in Press |
|
2025-05-13 07:39 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-05-20 03:03 |
|
Publish the Manuscript Online |
|
2025-05-29 09:14 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Minireviews |
| Article Title |
Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ana V Pejčić |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ana V Pejčić, Assistant Professor, PhD, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, Kragujevac 34000, Serbia. anapejcic201502@yahoo.com |
| Key Words |
Muscarinic receptors; Schizophrenia; Antipsychotic; Xanomeline; Trospium chloride; Review |
| Core Tip |
Xanomeline/trospium chloride is a potential new treatment option for a wide range of schizophrenia symptoms, offering a relatively favorable tolerability and safety profile. However, additional research is required to better understand its effectiveness and safety in real-world clinical practice, and to define its optimal role in managing this complex psychiatric disorder. As new evidence emerges, it is vital to evaluate it critically. |
| Publish Date |
2025-05-29 09:14 |
| Citation |
Pejčić AV. Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride. World J Psychiatry 2025; 15(6): 105409 |
| URL |
https://www.wjgnet.com/2220-3206/full/v15/i6/105409.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v15.i6.105409 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
